- Paper Report
- Open Access
neu/erbB-2oncogene in mouse mammary tumorigenesis
- Beatrice Howard1
© Current Science Ltd 2000
Published: 1 December 2000
Also known as c-erB-2 and Her-2, neu is a proto-oncogene that is amplified and overexpressed in about a quarter of human breast cancers. This study further refines the genetically engineered mouse model of activated Neu and shows that, as in human erb-B-2-positive breast tumors, mammary tumorigenesis in this model requires the amplification and overexpression of the neu gene.
To determine whether mice genetically engineered to produce activated Neu under the transcriptional control of the intact endogenous promoter can develop mammary tumours (as neu can when driven by strong viral promoters such as mouse mammary tumour virus [MMTV]).
The use of mice as models for human breast cancer has often been undermined by the fact that many of the genes engineered for expression in transgenic mice are driven by strong viral promoters whose relevance to human disease is questionable. In this study, a murine model transgenic for neu has been further refined by producing a conditionally expressed activated Neu protein that uses the intact endogenous neu promoter. These mice form numerous lobular side buds and, following a long latency period, develop tumors that are associated with a selective amplification of the activated neu allele and elevated levels of neu RNA and protein.
Transgenic mice were generated that conditionally expressed activated neu allele. This was achieved initially by constructing a transgenic line of mice that have exon one of neu replaced by a loxp-flanked cassette containing oncogenic neu, generated by an activating mutation in the transmembrane domain region of neu. This line was then crossed with a line containing the Cre recombinase gene driven by the MMTV promoter. In theory, this should induce loxp-mediated excision specifically in the mouse mammary gland.
Transgenic mice were generated that conditionally expressed activated neu mainly in the mammary gland. Cre-mediated excision of the neu cassette was also observed in the spleen and salivary glands, without any apparent ill effects. Nulliparous mice displayed abnormal mammary gland development with numerous lobular side buds composed of acinar structures. No staining for Neu was observed around these highly branched structures. Focal comedo-adenocarcinomas occured in 45% of female mice 1 year or older. These tumours showed membrane and cytoplasmic immunoreactivity for Neu, whereas MMTV-neu-induced tumours expressed only membrane Neu. Elevated oncogenic neu RNA and protein expression were observed in tumours but not in adjacent normal tissue. Selective amplification of the activated neu allele, ranging from 2- to 22-fold compared to the wild-type allele, was observed. Tumour formation did not correlate with parity status.
In contrast to the transgenic murine model of MMTV-driven activated Neu, activated Neu driven by its own promoter is not sufficient for the induction of mammary tumours. Mammary tumours eventually developed after a long latency period in these mice. These data suggest that amplification and elevated expression of activated Neu is required for efficient transformation of mammary epithelial cells. This refined mouse model is encouraging in that it mimics human disease in the type of tumour that forms and in the extended latency period needed for tumour formation. It should be a useful system for determining the role of other transcription factors (such as the oestrogen receptor and c-myc) in neu-mediated tumorigenesis.